US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ODDITY Tech Ltd.

14.14

-0.2600-1.81%

Post-market: 14.10-0.0400-0.28%16:12 EDT

Volume:655.27K

Turnover:9.49M

Market Cap:652.20M

PE:17.90

High:15.18

Open:14.49

Low:14.07

Close:14.40

52wk High:64.23

52wk Low:9.25

Shares:46.12M

Float Shares:28.59M

Volume Ratio:0.81

T/O Rate:2.29%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.7900

EPS(LYR):1.80

ROE:16.40%

ROA:3.99%

PB:2.18

PE(LYR):7.86

Loading ...

Overview Company News Filings

Immix Biopharma to Participate in the Jefferies Global Healthcare Conference

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

Kodiak AI Expands Autonomous Trucking Beyond the Sunbelt with Demonstrations in Ohio and Indiana

Oddity Tech (ODD) Faces Investor Lawsuit Over Alleged Ad Algorithm Disclosures

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

Press Release: Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

ODDITY Tech Is Maintained at Neutral by Goldman Sachs

Oddity Tech Faces Securities Lawsuit After Stock Drops Nearly 50% on Advertising Disruption Disclosure

Oddity Tech director Michael Farello files initial beneficial ownership statement

Key Corporate Announcements Summary for March 24 Evening

Belief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese Patients

Oddity Tech Director Lilach Payorski Files Initial Beneficial Ownership Statement

Oddity Tech Ltd. director Cheresniya Ohad files initial beneficial ownership statement

Oddity Tech Ltd. CTO Niv Price Files Initial Beneficial Ownership Statement

Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China

ODDITY Tech’s Exchangeable Notes Raise Dilution Risks and May Fuel Short Selling Pressure

Oddity Tech Ltd. files initial beneficial ownership statement for Chief Product Officer Shiran Holtzman-Erel

Oddity Tech Ltd. CFO Lindsay Drucker Mann Files Initial Beneficial Ownership Statement

Oddity Tech FY2025 net revenue rose 25.2% to USD 809.84 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/ODD/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ODD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","market":"US","secType":"STK","nameCN":"ODDITY Tech Ltd.","latestPrice":14.14,"timestamp":1788292800000,"preClose":14.4,"halted":0,"volume":655268,"hourTrading":{"tag":"盘后","latestPrice":14.1,"preClose":14.14,"latestTime":"16:12 EDT","volume":13751,"amount":194437.943663,"timestamp":1788293575857,"change":-0.04,"changeRate":-0.002829,"amplitude":0.002829},"delay":0,"changeRate":-0.01805555555555554,"floatShares":28586000,"shares":46124600,"eps":0.79,"marketStatus":"Post-Mkt","change":-0.26,"latestTime":"09-01 19:18:11 EDT","open":14.49,"high":15.175,"low":14.07,"amount":9491503,"amplitude":0.076736,"askPrice":15.43,"askSize":1,"bidPrice":13.5,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.79,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":4,"adr":0,"listingDate":1689739200000,"exchange":"NASDAQ","adjPreClose":14.4,"preHourTrading":{"tag":"盘前","latestPrice":14.37,"preClose":14.4,"latestTime":"09:29 EDT","volume":572,"amount":8220.167384,"timestamp":1788269399999,"change":-0.03,"changeRate":-0.002083,"amplitude":0.011632},"postHourTrading":{"tag":"盘后","latestPrice":14.1,"preClose":14.14,"latestTime":"16:12 EDT","volume":13751,"amount":194437.943663,"timestamp":1788293575857,"change":-0.04,"changeRate":-0.002829,"amplitude":0.002829},"volumeRatio":0.806401,"impliedVol":1.3388,"impliedVolPercentile":0.9802},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","floatShares":28586000,"roa":"3.99%","roe":"16.40%","lyrEps":1.8,"volumeRatio":0.806401,"shares":46124600,"dividePrice":0,"high":15.175,"amplitude":0.076736,"preClose":14.4,"low":14.07,"week52Low":9.2501,"pbRate":"2.18","psRate":"0.88","week52High":64.23,"institutionHeld":0,"latestPrice":14.14,"committee":0.980198,"eps":0.79,"divideRate":0,"volume":655268,"delay":0,"ttmEps":0.79,"open":14.49,"prevYearClose":40.18,"prevWeekClose":14.35,"prevMonthClose":14.4,"prevQuarterClose":15.13,"fiveDayClose":14.2,"twentyDayClose":15.31,"sixtyDayClose":9.81,"earningDate":1788883200000,"earningTime":"盘前"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ODD\",params:#limit:5,,,undefined,":[{"date":"2026-09-09","symbol":"ODD","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2026/06","expectedEps":0,"defaultRemindTime":1788940800000,"name":null,"time":"Pre-MKt","dateTimestamp":1788926400000,"actualEps":null},{"market":"US","date":"2026-06-02","symbol":"ODD","fiscalQuarterEnding":"2026/03","expectedEps":-0.08,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1780372800000,"reportTimeType":"pre","actualEps":-0.29},{"market":"US","date":"2026-02-25","symbol":"ODD","fiscalQuarterEnding":"2025/12","expectedEps":0.04,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771995600000,"reportTimeType":"pre","actualEps":0.1},{"market":"US","date":"2025-11-19","symbol":"ODD","fiscalQuarterEnding":"2025/09","expectedEps":0.24,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763528400000,"reportTimeType":"post","actualEps":0.28},{"market":"US","date":"2025-08-04","symbol":"ODD","fiscalQuarterEnding":"2025/06","expectedEps":0.79,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754280000000,"reportTimeType":"post","actualEps":0.76}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ODD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ODD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0.7,"sell":0.3,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.7,"analysts":10,"updateTime":1780545600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ODD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ODD","date":"2026-08-31","current":17.898734,"percent":0.120779,"low":6.104615,"twenty":18.932683,"median":26.737148,"eighty":37.364461,"high":144.174884,"avg":28.978641,"sd":16.660608,"marketCap":661887349},"quantilePoints":[{"date":"2023-07-21","current":130.121737,"twenty":124.979326,"median":126.90773,"eighty":128.836134,"marketCap":2827285100},{"date":"2023-07-28","current":127.857619,"twenty":126.192061,"median":128.560276,"eighty":129.606455,"marketCap":2778090339},{"date":"2023-08-04","current":144.174884,"twenty":128.138682,"median":130.121737,"eighty":138.668132,"marketCap":3132631890},{"date":"2023-08-11","current":59.921033,"twenty":128.138682,"median":131.59899,"eighty":138.150305,"marketCap":3096718967},{"date":"2023-08-18","current":49.805463,"twenty":52.028567,"median":129.262933,"eighty":135.506534,"marketCap":2573946329},{"date":"2023-08-25","current":45.155781,"twenty":48.598524,"median":91.807378,"eighty":132.13135,"marketCap":2333650744},{"date":"2023-09-01","current":45.716381,"twenty":47.266275,"median":50.709145,"eighty":131.711973,"marketCap":2362622552},{"date":"2023-09-08","current":40.286255,"twenty":46.134083,"median":49.805463,"eighty":131.410685,"marketCap":2081993665},{"date":"2023-09-15","current":40.648996,"twenty":43.649855,"median":48.206104,"eighty":130.121737,"marketCap":2100740129},{"date":"2023-09-22","current":30.701094,"twenty":40.692965,"median":47.574055,"eighty":129.262933,"marketCap":1586632553},{"date":"2023-09-29","current":31.151773,"twenty":36.878686,"median":46.562777,"eighty":127.857619,"marketCap":1609923614},{"date":"2023-10-06","current":28.491671,"twenty":32.503808,"median":45.749357,"eighty":123.693723,"marketCap":1472449544},{"date":"2023-10-13","current":31.976185,"twenty":32.503808,"median":44.402818,"eighty":59.921033,"marketCap":1652529215},{"date":"2023-10-20","current":29.832714,"twenty":31.459553,"median":41.803173,"eighty":57.306257,"marketCap":1541754654},{"date":"2023-10-27","current":29.832714,"twenty":31.15617,"median":40.714949,"eighty":54.667412,"marketCap":1541754654},{"date":"2023-11-03","current":29.678824,"twenty":30.355941,"median":40.467625,"eighty":50.479578,"marketCap":1533801609},{"date":"2023-11-10","current":30.298177,"twenty":30.305454,"median":36.878686,"eighty":50.003322,"marketCap":1598562121},{"date":"2023-11-17","current":37.221321,"twenty":30.355941,"median":36.411519,"eighty":49.783479,"marketCap":1963834134},{"date":"2023-11-24","current":37.016749,"twenty":30.445709,"median":37.119035,"eighty":49.462508,"marketCap":1953040715},{"date":"2023-12-01","current":36.693741,"twenty":30.5941,"median":37.016749,"eighty":48.26876,"marketCap":1935998475},{"date":"2023-12-08","current":40.591374,"twenty":30.734071,"median":37.17287,"eighty":48.041138,"marketCap":2141641505},{"date":"2023-12-15","current":46.060981,"twenty":30.923136,"median":37.910406,"eighty":47.753992,"marketCap":2430223438},{"date":"2023-12-22","current":50.712301,"twenty":31.153971,"median":38.59949,"eighty":48.041138,"marketCap":2675631695},{"date":"2023-12-29","current":50.884572,"twenty":31.160567,"median":38.868664,"eighty":49.761494,"marketCap":2684720890},{"date":"2024-01-05","current":46.7716,"twenty":31.28148,"median":39.765881,"eighty":49.183424,"marketCap":2467716366},{"date":"2024-01-12","current":46.965405,"twenty":31.46395,"median":40.526773,"eighty":48.323896,"marketCap":2477941710},{"date":"2024-01-19","current":45.899477,"twenty":31.472743,"median":40.645209,"eighty":48.306372,"marketCap":2421702318},{"date":"2024-01-26","current":45.684138,"twenty":31.580467,"median":40.703957,"eighty":48.306372,"marketCap":2410340824},{"date":"2024-02-02","current":45.156558,"twenty":31.989432,"median":42.12028,"eighty":48.252127,"marketCap":2382505165},{"date":"2024-02-09","current":48.246671,"twenty":32.113484,"median":43.346019,"eighty":48.217673,"marketCap":2545542596},{"date":"2024-02-16","current":46.125583,"twenty":32.418946,"median":44.467474,"eighty":48.217673,"marketCap":2433631886},{"date":"2024-02-23","current":42.389454,"twenty":32.503808,"median":43.451996,"eighty":48.101679,"marketCap":2236509975},{"date":"2024-03-01","current":45.414965,"twenty":32.586249,"median":43.346019,"eighty":47.880595,"marketCap":2396138958},{"date":"2024-03-08","current":42.187798,"twenty":32.646706,"median":43.451996,"eighty":47.880595,"marketCap":2469420590},{"date":"2024-03-15","current":43.718187,"twenty":32.976471,"median":43.684021,"eighty":47.798976,"marketCap":2559000375},{"date":"2024-03-22","current":43.038127,"twenty":33.910804,"median":43.451996,"eighty":47.751391,"marketCap":2519193702},{"date":"2024-03-28","current":41.755726,"twenty":34.121582,"median":43.229275,"eighty":47.682483,"marketCap":2444129691},{"date":"2024-04-05","current":35.33401,"twenty":34.429566,"median":43.074483,"eighty":47.592295,"marketCap":2068240969},{"date":"2024-04-12","current":35.168853,"twenty":35.003425,"median":42.938568,"eighty":47.491972,"marketCap":2058573635},{"date":"2024-04-19","current":32.672059,"twenty":33.859301,"median":42.736957,"eighty":47.44561,"marketCap":1912426280},{"date":"2024-04-26","current":30.816464,"twenty":32.666988,"median":42.389454,"eighty":47.239294,"marketCap":1803810931},{"date":"2024-05-03","current":32.701204,"twenty":32.521826,"median":42.280345,"eighty":47.139393,"marketCap":1914132280},{"date":"2024-05-10","current":30.051334,"twenty":32.188614,"median":42.12028,"eighty":47.109682,"marketCap":2161502316},{"date":"2024-05-17","current":34.470881,"twenty":32.029175,"median":41.880975,"eighty":47.036466,"marketCap":2479387030},{"date":"2024-05-24","current":28.991908,"twenty":31.962852,"median":41.668069,"eighty":46.979437,"marketCap":2085300972},{"date":"2024-05-31","current":28.39104,"twenty":31.618936,"median":40.692965,"eighty":46.967038,"marketCap":2042082299},{"date":"2024-06-07","current":35.032218,"twenty":31.466148,"median":40.618291,"eighty":46.952485,"marketCap":2519762369},{"date":"2024-06-14","current":31.434913,"twenty":31.466148,"median":40.526773,"eighty":46.846969,"marketCap":2261018998},{"date":"2024-06-21","current":31.17401,"twenty":31.40776,"median":40.286255,"eighty":46.77806,"marketCap":2242252995},{"date":"2024-06-28","current":31.039605,"twenty":31.15617,"median":39.116208,"eighty":46.676851,"marketCap":2232585660},{"date":"2024-07-05","current":32.549682,"twenty":31.153971,"median":38.825596,"eighty":46.51104,"marketCap":2341201009},{"date":"2024-07-12","current":33.300768,"twenty":31.165014,"median":38.233414,"eighty":46.411983,"marketCap":2395224351},{"date":"2024-07-19","current":31.719535,"twenty":31.193823,"median":37.851188,"eighty":46.379683,"marketCap":2281491001},{"date":"2024-07-26","current":32.889648,"twenty":31.177172,"median":37.124419,"eighty":46.315081,"marketCap":2365653680},{"date":"2024-08-02","current":30.43083,"twenty":31.177172,"median":37.016749,"eighty":46.269497,"marketCap":2188798320},{"date":"2024-08-09","current":24.621128,"twenty":31.077829,"median":36.878686,"eighty":46.15167,"marketCap":2152403648},{"date":"2024-08-16","current":25.909103,"twenty":30.914687,"median":36.319047,"eighty":46.132383,"marketCap":2264999665},{"date":"2024-08-23","current":24.744722,"twenty":30.826367,"median":35.664326,"eighty":46.112663,"marketCap":2163208317},{"date":"2024-08-30","current":23.938111,"twenty":30.576415,"median":35.479654,"eighty":46.043754,"marketCap":2092693640},{"date":"2024-09-06","current":21.999645,"twenty":30.415298,"median":35.251431,"eighty":45.974846,"marketCap":1923230948},{"date":"2024-09-13","current":22.858294,"twenty":30.138302,"median":35.032218,"eighty":45.974846,"marketCap":1998294959},{"date":"2024-09-20","current":23.144511,"twenty":29.832714,"median":34.577614,"eighty":45.899477,"marketCap":2023316296},{"date":"2024-09-27","current":25.837549,"twenty":29.733784,"median":34.493388,"eighty":45.749357,"marketCap":2258744331},{"date":"2024-10-04","current":26.907033,"twenty":29.206161,"median":34.203986,"eighty":45.716381,"marketCap":2352239691},{"date":"2024-10-11","current":26.632604,"twenty":28.857503,"median":34.05976,"eighty":45.700078,"marketCap":2328248903},{"date":"2024-10-18","current":26.737148,"twenty":28.675661,"median":33.782046,"eighty":45.684138,"marketCap":2337388251},{"date":"2024-10-25","current":24.829219,"twenty":28.39104,"median":33.498422,"eighty":45.587236,"marketCap":2170595150},{"date":"2024-11-01","current":24.874957,"twenty":27.774359,"median":33.138619,"eighty":45.414965,"marketCap":2174593614},{"date":"2024-11-08","current":25.903059,"twenty":26.907033,"median":32.701204,"eighty":45.328829,"marketCap":2624135294},{"date":"2024-11-15","current":22.412856,"twenty":26.554196,"median":32.64481,"eighty":45.156558,"marketCap":2270556768},{"date":"2024-11-22","current":25.688798,"twenty":26.266873,"median":32.549682,"eighty":45.155781,"marketCap":2602429343},{"date":"2024-11-29","current":26.196259,"twenty":26.231703,"median":32.526331,"eighty":45.078881,"marketCap":2653838175},{"date":"2024-12-06","current":27.019473,"twenty":26.102043,"median":32.510933,"eighty":44.930453,"marketCap":2737234726},{"date":"2024-12-13","current":27.882156,"twenty":26.129486,"median":32.397731,"eighty":44.829243,"marketCap":2824629741},{"date":"2024-12-20","current":24.673876,"twenty":26.102043,"median":32.284642,"eighty":44.80743,"marketCap":2499611678},{"date":"2024-12-27","current":24.555468,"twenty":26.074468,"median":32.122117,"eighty":44.68052,"marketCap":2487616283},{"date":"2025-01-03","current":24.036731,"twenty":26.028044,"median":31.982415,"eighty":44.572573,"marketCap":2435065032},{"date":"2025-01-10","current":24.916329,"twenty":25.91918,"median":31.969518,"eighty":44.533395,"marketCap":2524173675},{"date":"2025-01-17","current":25.299744,"twenty":25.850651,"median":31.948814,"eighty":44.510542,"marketCap":2563015904},{"date":"2025-01-24","current":24.983991,"twenty":25.688798,"median":31.719535,"eighty":44.467474,"marketCap":2531028186},{"date":"2025-01-31","current":26.906704,"twenty":25.660605,"median":31.631647,"eighty":44.252135,"marketCap":2725810541},{"date":"2025-02-07","current":24.025454,"twenty":25.660605,"median":31.600943,"eighty":44.067933,"marketCap":2433922614},{"date":"2025-02-14","current":24.245353,"twenty":25.528357,"median":31.476041,"eighty":43.718187,"marketCap":2456199775},{"date":"2025-02-21","current":24.809199,"twenty":25.393274,"median":31.447233,"eighty":43.663521,"marketCap":2513320700},{"date":"2025-02-28","current":26.194867,"twenty":25.287339,"median":31.363758,"eighty":43.611255,"marketCap":2658543217},{"date":"2025-03-07","current":24.561126,"twenty":25.149762,"median":31.267028,"eighty":43.481918,"marketCap":2492733193},{"date":"2025-03-14","current":25.259729,"twenty":25.127573,"median":31.17401,"eighty":43.282433,"marketCap":2563635122},{"date":"2025-03-21","current":23.829518,"twenty":25.089994,"median":31.105558,"eighty":43.231428,"marketCap":2418481566},{"date":"2025-03-28","current":23.620487,"twenty":25.062794,"median":30.968449,"eighty":43.177394,"marketCap":2397266815},{"date":"2025-04-04","current":20.886583,"twenty":24.97973,"median":30.909153,"eighty":43.121556,"marketCap":2119800209},{"date":"2025-04-11","current":22.872376,"twenty":24.935811,"median":30.865977,"eighty":43.052669,"marketCap":2321340339},{"date":"2025-04-17","current":23.075906,"twenty":24.876099,"median":30.80242,"eighty":42.991494,"marketCap":2341996807},{"date":"2025-04-25","current":24.341093,"twenty":24.812177,"median":30.590011,"eighty":42.947303,"marketCap":2470401876},{"date":"2025-05-02","current":33.211688,"twenty":24.800183,"median":30.612672,"eighty":42.912727,"marketCap":3531697688},{"date":"2025-05-09","current":37.275211,"twenty":24.812177,"median":30.809442,"eighty":42.852836,"marketCap":3963808661},{"date":"2025-05-16","current":33.075187,"twenty":24.823197,"median":30.881482,"eighty":42.719469,"marketCap":3517182333},{"date":"2025-05-23","current":36.009954,"twenty":24.840888,"median":30.917059,"eighty":42.57047,"marketCap":3829262479},{"date":"2025-05-30","current":37.968215,"twenty":24.859184,"median":31.004027,"eighty":42.466444,"marketCap":4037502005},{"date":"2025-06-06","current":40.472479,"twenty":24.875718,"median":31.151773,"eighty":42.376534,"marketCap":4303802953},{"date":"2025-06-13","current":38.84497,"twenty":24.888137,"median":31.181916,"eighty":42.353632,"marketCap":4130735251},{"date":"2025-06-20","current":36.618957,"twenty":24.907308,"median":31.267028,"eighty":42.321149,"marketCap":3894023297},{"date":"2025-06-27","current":37.637463,"twenty":24.9212,"median":31.363758,"eighty":42.207431,"marketCap":4002330181},{"date":"2025-07-03","current":39.798375,"twenty":24.940682,"median":31.434913,"eighty":42.187798,"marketCap":4232119427},{"date":"2025-07-11","current":38.424967,"twenty":24.946182,"median":31.476041,"eighty":42.12028,"marketCap":4086072618},{"date":"2025-07-18","current":37.17546,"twenty":24.957184,"median":31.58513,"eighty":42.056896,"marketCap":3953201285},{"date":"2025-07-25","current":36.450956,"twenty":24.962685,"median":31.617964,"eighty":41.958776,"marketCap":3876158244},{"date":"2025-08-01","current":36.786958,"twenty":24.983991,"median":31.719535,"eighty":41.803173,"marketCap":3911888350},{"date":"2025-08-08","current":29.269388,"twenty":24.988656,"median":31.680004,"eighty":41.755726,"marketCap":3223525522},{"date":"2025-08-15","current":29.576073,"twenty":25.039696,"median":31.613107,"eighty":41.668069,"marketCap":3257301638},{"date":"2025-08-22","current":30.491058,"twenty":25.068568,"median":31.584654,"eighty":40.714949,"marketCap":3358071703},{"date":"2025-08-29","current":30.947283,"twenty":25.079845,"median":31.470545,"eighty":40.692965,"marketCap":3408317165},{"date":"2025-09-05","current":31.494754,"twenty":25.083205,"median":31.459553,"eighty":40.65779,"marketCap":3468611719},{"date":"2025-09-12","current":31.935772,"twenty":25.085195,"median":31.488146,"eighty":40.645966,"marketCap":3517182333},{"date":"2025-09-19","current":31.793835,"twenty":25.089994,"median":31.584179,"eighty":40.616226,"marketCap":3501550411},{"date":"2025-09-26","current":29.994279,"twenty":25.105422,"median":31.49222,"eighty":40.594895,"marketCap":3303359978},{"date":"2025-10-03","current":30.739447,"twenty":25.114201,"median":31.481537,"eighty":40.590201,"marketCap":3385427566},{"date":"2025-10-10","current":26.927161,"twenty":25.127573,"median":31.451808,"eighty":40.571566,"marketCap":2965569012},{"date":"2025-10-17","current":26.01968,"twenty":25.135101,"median":31.389658,"eighty":40.56278,"marketCap":2865625373},{"date":"2025-10-24","current":24.575011,"twenty":25.135101,"median":31.29655,"eighty":40.533764,"marketCap":2706519695},{"date":"2025-10-31","current":22.697464,"twenty":25.089994,"median":31.260978,"eighty":40.483338,"marketCap":2499739752},{"date":"2025-11-07","current":20.840778,"twenty":25.062794,"median":31.168388,"eighty":40.3235,"marketCap":2295257365},{"date":"2025-11-14","current":21.127625,"twenty":24.961585,"median":31.125566,"eighty":40.286255,"marketCap":2326848745},{"date":"2025-11-21","current":20.632506,"twenty":24.914074,"median":31.026394,"eighty":40.195833,"marketCap":2272856204},{"date":"2025-11-28","current":22.556538,"twenty":24.864441,"median":30.973992,"eighty":40.067661,"marketCap":2484805645},{"date":"2025-12-05","current":23.453377,"twenty":24.800183,"median":30.947283,"eighty":39.942199,"marketCap":2583600507},{"date":"2025-12-12","current":23.171811,"twenty":24.744189,"median":30.91898,"eighty":39.889726,"marketCap":2552583516},{"date":"2025-12-19","current":22.108118,"twenty":24.698354,"median":30.913106,"eighty":39.830715,"marketCap":2435408215},{"date":"2025-12-26","current":21.97255,"twenty":24.603474,"median":30.881482,"eighty":39.790815,"marketCap":2420474108},{"date":"2026-01-02","current":20.950571,"twenty":24.5566,"median":30.865977,"eighty":39.747975,"marketCap":2307893917},{"date":"2026-01-09","current":20.079803,"twenty":24.511489,"median":30.793745,"eighty":39.569474,"marketCap":2211970999},{"date":"2026-01-16","current":18.426908,"twenty":24.453976,"median":30.739447,"eighty":39.33668,"marketCap":2029889771},{"date":"2026-01-23","current":18.270483,"twenty":24.345533,"median":30.673548,"eighty":39.245507,"marketCap":2012658109},{"date":"2026-01-30","current":17.535284,"twenty":24.313015,"median":30.590011,"eighty":39.075971,"marketCap":1931669298},{"date":"2026-02-06","current":15.001193,"twenty":24.204717,"median":30.513869,"eighty":38.986908,"marketCap":1652516376},{"date":"2026-02-13","current":14.396348,"twenty":24.048695,"median":30.485989,"eighty":38.976221,"marketCap":1585887283},{"date":"2026-02-20","current":15.950173,"twenty":23.978855,"median":30.423064,"eighty":38.890175,"marketCap":1757055125},{"date":"2026-02-27","current":7.139339,"twenty":23.850132,"median":30.333914,"eighty":38.866509,"marketCap":790646086},{"date":"2026-03-06","current":7.224918,"twenty":23.762072,"median":30.274296,"eighty":38.85757,"marketCap":800123500},{"date":"2026-03-13","current":6.950028,"twenty":23.706908,"median":30.138302,"eighty":38.84707,"marketCap":769680898},{"date":"2026-03-20","current":7.187922,"twenty":23.614586,"median":30.055287,"eighty":38.79877,"marketCap":796026424},{"date":"2026-03-27","current":6.865617,"twenty":23.526973,"median":29.994279,"eighty":38.783466,"marketCap":760332712},{"date":"2026-04-02","current":6.855385,"twenty":23.427349,"median":29.832714,"eighty":38.753843,"marketCap":759199579},{"date":"2026-04-10","current":7.072813,"twenty":23.171299,"median":29.799737,"eighty":38.548868,"marketCap":783278670},{"date":"2026-04-17","current":7.668822,"twenty":23.13114,"median":29.705337,"eighty":38.419858,"marketCap":849283708},{"date":"2026-04-24","current":7.92462,"twenty":22.959771,"median":29.615359,"eighty":38.380611,"marketCap":877612050},{"date":"2026-05-01","current":7.326053,"twenty":22.880081,"median":29.470231,"eighty":38.282735,"marketCap":811323729},{"date":"2026-05-08","current":7.617663,"twenty":22.847068,"median":29.327683,"eighty":38.184209,"marketCap":843618039},{"date":"2026-05-15","current":6.415412,"twenty":22.722307,"median":29.206161,"eighty":38.041491,"marketCap":710474829},{"date":"2026-05-22","current":6.338673,"twenty":22.581017,"median":28.928656,"eighty":37.95404,"marketCap":701976327},{"date":"2026-05-29","current":6.701906,"twenty":22.463575,"median":28.85355,"eighty":37.93304,"marketCap":742202573},{"date":"2026-06-05","current":11.066918,"twenty":22.355552,"median":28.723098,"eighty":37.913591,"marketCap":570532817},{"date":"2026-06-12","current":12.045027,"twenty":22.082048,"median":28.568928,"eighty":37.870529,"marketCap":620957267},{"date":"2026-06-18","current":12.056017,"twenty":22.028863,"median":28.441356,"eighty":37.806965,"marketCap":621523834},{"date":"2026-06-26","current":14.440844,"twenty":21.88078,"median":28.164079,"eighty":37.786268,"marketCap":744468840},{"date":"2026-07-02","current":18.69397,"twenty":21.779625,"median":28.062977,"eighty":37.763464,"marketCap":963730211},{"date":"2026-07-10","current":19.045649,"twenty":21.529345,"median":27.910348,"eighty":37.653213,"marketCap":981860351},{"date":"2026-07-17","current":14.619425,"twenty":21.127625,"median":27.658443,"eighty":37.642713,"marketCap":753675212},{"date":"2026-07-24","current":13.894717,"twenty":20.840778,"median":27.290118,"eighty":37.637463,"marketCap":716314323},{"date":"2026-07-31","current":13.102906,"twenty":20.627222,"median":27.097913,"eighty":37.608063,"marketCap":675494093},{"date":"2026-08-07","current":12.096366,"twenty":20.299418,"median":26.927161,"eighty":37.545851,"marketCap":623603970},{"date":"2026-08-14","current":11.926373,"twenty":19.78552,"median":26.9103,"eighty":37.435797,"marketCap":614840304},{"date":"2026-08-21","current":11.192718,"twenty":19.351603,"median":26.903692,"eighty":37.382312,"marketCap":577018170},{"date":"2026-08-28","current":13.411578,"twenty":19.023056,"median":26.740169,"eighty":37.366561,"marketCap":691407064},{"date":"2026-08-31","current":12.838969,"twenty":18.932683,"median":26.737148,"eighty":37.364461,"marketCap":661887349}],"updateTime":1788304691646},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ODD\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2626484187","title":"Immix Biopharma to Participate in the Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2626484187","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626484187?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:45","pubTimestamp":1775738700,"startTime":"0","endTime":"0","summary":"LOS ANGELES, CA, April  09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270986/0/en/Immix-Biopharma-to-Participate-in-the-Jefferies-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","XLV","BK4183","LU0128526141.USD","XBI","IE0009354923.USD","BK4137","BK4581","LABU","LU0029874061.USD","BK4585","BK4588","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626215188","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2626215188","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626215188?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:34","pubTimestamp":1775723640,"startTime":"0","endTime":"0","summary":"NANJING, China, April  09, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) announced that its proprietary PD-L1/4-1BB bispecific antibo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270693/0/en/Leads-Biolabs-Opamtistomig-PD-L1-4-1BB-Bispecific-Antibody-Advances-to-Expansion-Phase-in-First-Line-Biliary-Tract-Cancer-Following-Positive-Safety-and-Preliminary-Efficacy-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4086","IE0009354923.USD","LU2023250843.SGD","IE00B3CCJ633.GBP","LU2023250504.SGD","IE00B2PGVK34.USD","PD","LU2106854487.HKD","OC","BTC","BK4006","BK4023","LU2048586759.USD","BK4183","HCC","LU2041044095.USD","LU0868494617.USD","LU1169589451.USD","LU2092937221.SGD","LU1974910355.USD","LU2360108059.USD","LU1169590202.USD","IE00BGHQF417.EUR","LU2298321311.HKD","LU1917777945.USD","ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625949165","title":"Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2625949165","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625949165?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:30","pubTimestamp":1775647800,"startTime":"0","endTime":"0","summary":"HOUSTON, April  08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/08/3270005/0/en/Plus-Therapeutics-Granted-U-S-FDA-Orphan-Drug-Designation-to-REYOBIQ-in-Pediatric-Malignant-Gliomas.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","LENZ","LABU","IE0009354923.USD","NCI","ODD","CNS","IND","BK4135","BK4202","BK4007","CSF","BK4539","BK4183","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625966700","title":"Kodiak AI Expands Autonomous Trucking Beyond the Sunbelt with Demonstrations in Ohio and Indiana","url":"https://stock-news.laohu8.com/highlight/detail?id=2625966700","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625966700?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:30","pubTimestamp":1775593800,"startTime":"0","endTime":"0","summary":"Milestone program with DriveOhio’s Ohio Truck Automation Project marks Kodiak’s operational expansion outside of the Sunbelt, showcases how driverless trucks can transform critical Northern freight corridors","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/07/3269653/0/en/Kodiak-AI-Expands-Autonomous-Trucking-Beyond-the-Sunbelt-with-Demonstrations-in-Ohio-and-Indiana.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4587","BK4543","ARTY","AI","BK4528","AIYY","BK4585","BK4588","AGIX","TRC","AIPO","IE0009354923.USD","BK4193","BK4183","ODD","ODOT","BK4551","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625963898","title":"Oddity Tech (ODD) Faces Investor Lawsuit Over Alleged Ad Algorithm Disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2625963898","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625963898?lang=en_us&edition=fundamental","pubTime":"2026-04-08 02:46","pubTimestamp":1775587599,"startTime":"0","endTime":"0","summary":"Oddity Tech (ODD) told investors its AI-powered beauty platform was thriving. Growth was strong. Guidance kept rising. But behind the scenes, an al...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/oddity-tech-odd-faces-investor-lawsuit-over-alleged-ad-algorithm-disclosures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/oddity-tech-odd-faces-investor-lawsuit-over-alleged-ad-algorithm-disclosures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIX","BK4023","BK4543","BK4588","IE0009354923.USD","BK4585","AIPO","ARTY","BK4587","AIYY","BK4183","CHAT","ODD","BK4551","AI","BK4528"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623343315","title":"Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2623343315","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623343315?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:45","pubTimestamp":1774874700,"startTime":"0","endTime":"0","summary":"– Full enrollment of BLA-enabling trial complete, per prior guidance –– Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch –– Onboarded Chief Medical","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264634/0/en/Immix-Biopharma-Announces-Enrollment-Completion-of-BLA-Enabling-Relapsed-Refractory-AL-Amyloidosis-Trial-NEXICART-2-and-Upcoming-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AL","BK4585","LU1169589451.USD","BK4572","BK4104","ODD","IE00B19Z6F94.USD","BK4183","CAR","BK4022","IE0034390439.USD","BK4588","LABU","IE0009354923.USD","LU1169590202.USD","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623311997","title":"Press Release: Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623311997","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623311997?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:05","pubTimestamp":1774868700,"startTime":"0","endTime":"0","summary":"under review by U.S. Food and Drug Administration  with a. Prescription Drug User Fee Act  target action date of June 29,-- Commercial readiness activities ongoing in anticipation of potential. securities totaled $54.9 million, with expected runway into 2027. \"This year is shaping up to be pivotal for Unicycive, underscored by the U.S. Food and Drug Administration's acceptance of our New Drug Application resubmission for OLC and the potential for approval and launch later this year,\" said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. \"With hyperphosphatemia still uncontrolled in nearly 75% of U.S. patients with chronic kidney disease undergoing dialysis, OLC, if approved, has the potential to offer a meaningful new treatment option characterized by a differentiated clinical profile and reduced pill burden compared to currently available phosphate binders.\". resubmission of its NDA for OLC, an investigational oral phosphate binder. launch of OLC later this year, the Company","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","LU0971096721.USD","LU2237443895.HKD","LU2237443549.SGD","LU2237443382.USD","IE00BKVL7J92.USD","IE00B1BXHZ80.USD","LABU","LU0882574139.USD","LU2237443978.SGD","ODD","CMC","LU0170899867.USD","LU2746668461.USD","IE00BHPRN162.USD","BK4539","LU2746668974.SGD","UNCY","BK4006","LU0267386448.USD","IE00BZ1G4Q59.USD","IE0009354923.USD","LU0149725797.USD","BK4183","BK4585","BK4588","LU1363072403.SGD","LU2237443622.USD","IE00BFXG1179.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622874140","title":"ODDITY Tech Is Maintained at Neutral by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2622874140","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622874140?lang=en_us&edition=fundamental","pubTime":"2026-03-28 01:36","pubTimestamp":1774632960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 13:36 ET (17:36 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622009503","title":"Oddity Tech Faces Securities Lawsuit After Stock Drops Nearly 50% on Advertising Disruption Disclosure","url":"https://stock-news.laohu8.com/highlight/detail?id=2622009503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622009503?lang=en_us&edition=fundamental","pubTime":"2026-03-26 02:08","pubTimestamp":1774462113,"startTime":"0","endTime":"0","summary":"Oddity Tech (ODD) told investors its AI-driven beauty platform was delivering strong growth and profitability. But behind the scenes, something was...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/oddity-tech-faces-securities-lawsuit-after-stock-drops-nearly-50-on-advertising-disruption-disclosure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/oddity-tech-faces-securities-lawsuit-after-stock-drops-nearly-50-on-advertising-disruption-disclosure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","ODD","CHAT","BK4528","AI","BK4588","AIYY","BK4183","BK4587","AIPO","BK4551","AGIX","BK4023","BK4585","BK4543"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622013950","title":"Oddity Tech director Michael Farello files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2622013950","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622013950?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:27","pubTimestamp":1774384050,"startTime":"0","endTime":"0","summary":"Oddity director Michael Farello filed an initial Form 3 reporting direct ownership of 57,143 Class A ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oddity Tech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDLQkVpJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","ODD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167521893","title":"Key Corporate Announcements Summary for March 24 Evening","url":"https://stock-news.laohu8.com/highlight/detail?id=1167521893","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167521893?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:31","pubTimestamp":1774351864,"startTime":"0","endTime":"0","summary":"Jiuzhitong announced that its invested company, GALAXIS TECH Group Co., Ltd., was listed on the Main Board of the Hong Kong Stock Exchange on March 24. The company's investment cost was 26.6 million...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","02729","BK4183","PID","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621722962","title":"Belief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2621722962","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621722962?lang=en_us&edition=fundamental","pubTime":"2026-03-23 14:02","pubTimestamp":1774245720,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 23, 2026 /PRNewswire/ -- Belief BioMed  and Grand Life Sciences Group Co., Ltd.  today announced an exclusive collaboration agreement. Under the agreement, Belief BioMed will grant Grand Life Sciences the rights to commercialize its investigational product, BBM-H803, in Mainland China, Hong Kong China, Macau China, and Taiwan China. The collaboration underscores the shared commitment of both sides to leverage their respective strengths and resources in their respective fields,to accelerate the commercialization process of the product,help hemophilia A patients access innovative treatment option, and jointly promote the development of the gene therapy industry. The agreement was signed by Xiao Xiao, Co-founder, Chairman and CSO of Belief BioMed, and Zenghui, Feng, Chairman of Grand Life Sciences.Signing Ceremony for the Exclusive Commercial Collaboration Between Belief BioMed and Grand Life Sciences . About Hemophilia AHemophilia A is a genetic disorder caused by the def","market":"us","thumbnail":"https://mma.prnewswire.com/media/2939687/image1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2939687/image1.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/belief-biomed-and-grand-life-sciences-announced-exclusive-commercial-partnership-in-the-field-of-hemophilia-a-bringing-innovative-gene-therapy-to-chinese-patients-302721797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","IND.AU","IE0009354923.USD","IND","BK7095","BLA.AU","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621757774","title":"Oddity Tech Director Lilach Payorski Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2621757774","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621757774?lang=en_us&edition=fundamental","pubTime":"2026-03-21 07:10","pubTimestamp":1774048222,"startTime":"0","endTime":"0","summary":"Oddity director Lilach Payorski reported direct ownership of 10,917 Class A ordinary shares in an initial Form 3 filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oddity Tech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL74Smjs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","BK4183","ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621575779","title":"Oddity Tech Ltd. director Cheresniya Ohad files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2621575779","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621575779?lang=en_us&edition=fundamental","pubTime":"2026-03-21 07:09","pubTimestamp":1774048142,"startTime":"0","endTime":"0","summary":"Oddity director Cheresniya Ohad filed an initial Form 3 reporting 9,961 Class A ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oddity Tech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL4Fvf1f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","ODD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621757222","title":"Oddity Tech Ltd. CTO Niv Price Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2621757222","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621757222?lang=en_us&edition=fundamental","pubTime":"2026-03-21 07:04","pubTimestamp":1774047889,"startTime":"0","endTime":"0","summary":"Oddity CTO Niv Price filed an initial beneficial ownership statement reporting 41,227 Class A ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oddity Tech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL8QstWL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","BK4183","ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620896241","title":"Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China","url":"https://stock-news.laohu8.com/highlight/detail?id=2620896241","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620896241?lang=en_us&edition=fundamental","pubTime":"2026-03-19 18:27","pubTimestamp":1773916020,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 19, 2026 /PRNewswire/ -- Belief BioMed  today announced that BBM-H901 , has been officially approved by the Pharmaceutical Administration Bureau of Macao Special Administrative Region of China for the treatment of adult patients with moderate to severe hemophilia B . This product is developed and manufactured by BBM, and Takeda China is responsible for its commercialization in mainland China, Hong Kong, China and Macao, China. Following its approval in mainland China in April 2025 as the country's first gene therapy for hemophilia B, [1] the recent approval of BBM-H901 in Macao, China, not only addresses the previously unmet medical need for such treatment in the region but also marks a crucial step in accelerating the global availability of this breakthrough gene therapy.BBM-H901 is a gene therapy drug based on a recombinant adeno-associated virus  vector. It can precisely deliver the high-activity FIX gene into the liver cells of patients, enabling the sustained and h","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/belief-biomed-announced-bbm-h901-dalnacogene-ponparvovec-injection-chinas-first-hemophilia-b-gene-therapy-was-officially-approved-in-macao-china-302718633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABR.AU","ASH.AU","BK4183","FIX","ATMP","IE0009354923.USD","EMA.AU","LU0053671581.USD","EMA","ASH","BK7057","BK4567","LU0963586101.USD","BK4110","BLA.AU","BK7129","BK7095","ODD","BK4129","BK7504","BK4109","LU0054578231.USD","LU2463526074.USD","ABR","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620219955","title":"ODDITY Tech’s Exchangeable Notes Raise Dilution Risks and May Fuel Short Selling Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=2620219955","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620219955?lang=en_us&edition=fundamental","pubTime":"2026-03-19 14:01","pubTimestamp":1773900070,"startTime":"0","endTime":"0","summary":"ODDITY Tech Ltd. Class A (ODD) has disclosed a new risk, in the Debt & Financing category. The analyst notes that exchanges of ODDITY Tech Ltd. Cla...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oddity-techs-exchangeable-notes-raise-dilution-risks-and-may-fuel-short-selling-pressure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oddity-techs-exchangeable-notes-raise-dilution-risks-and-may-fuel-short-selling-pressure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","IE0009354923.USD","ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620291188","title":"Oddity Tech Ltd. files initial beneficial ownership statement for Chief Product Officer Shiran Holtzman-Erel","url":"https://stock-news.laohu8.com/highlight/detail?id=2620291188","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620291188?lang=en_us&edition=fundamental","pubTime":"2026-03-19 08:41","pubTimestamp":1773880899,"startTime":"0","endTime":"0","summary":"Oddity Tech reported an initial statement of beneficial ownership for Shiran Holtzman-Erel. Holtzman-Erel is a director and Chief Product Officer. The filing reported a performance stock option covering 1,095,256 Class A ordinary shares. The option has an exercise price of USD 27.74 and an expiration date of June 21, 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oddity Tech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL8cj43V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","IE0009354923.USD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620299824","title":"Oddity Tech Ltd. CFO Lindsay Drucker Mann Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620299824","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620299824?lang=en_us&edition=fundamental","pubTime":"2026-03-19 08:08","pubTimestamp":1773878911,"startTime":"0","endTime":"0","summary":"Oddity Tech reported an initial statement of beneficial ownership by Lindsay Drucker Mann, its global chief financial officer. Drucker Mann reported direct ownership of 34,729 Class A ordinary shares. Drucker Mann also reported stock options covering 426,840 Class A ordinary shares at an exercise price of USD 9.39. The filing also listed stock options covering 717,876 shares at an exercise price of USD 13.93. It also reported restricted stock units covering 0.86 million Class A ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oddity Tech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL3vkG4M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","BK4183","ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620408080","title":"Oddity Tech FY2025 net revenue rose 25.2% to USD 809.84 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620408080","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620408080?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:21","pubTimestamp":1773778902,"startTime":"0","endTime":"0","summary":"Oddity published its annual report on Form 20-F for the fiscal year ended Dec. 31, 2025, reporting net revenue of USD 809.84 million, up 25.2%. Net income was USD 110.75 million, while operating income was USD 118.77 million. Adjusted EBITDA rose 8.6% to USD 163.35 million, and adjusted EBITDA margin was 20.2%. The company said it has experienced a significant increase in customer acquisition costs that is adversely impacting revenue and margins, and it does not expect to achieve its long-term targets while those costs remain elevated. Oddity ended the year with USD 776 million of cash and cash equivalents, restricted cash, short-term deposits and marketable securities, and said it believes existing liquidity and positive operating cash flows will be sufficient for at least the next 12 months.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL5D4yfV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","IE0009354923.USD","ODD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":129,"code":"91000000","status":"200"}]}}